Clinical Trial Update: Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL [Phase 2]

View source ↗

Summary

An update on a Phase II trial evaluating MOR00208 in combination with lenalidomide for relapsed/refractory or untreated older patients with chronic lymphocytic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• MOR00208

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED